# Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis

## TL;DR

This review explores muscle pathology in ALS, highlighting how muscle changes could be a new target for therapy alongside CNS treatments.

## Contribution

The paper systematically reviews muscle-specific pathological features in ALS, emphasizing their therapeutic potential.

## Key findings

- ALS muscle shows histopathological changes like fiber type grouping and inflammation.
- Muscle alterations include protein misfolding and mitochondrial dysfunction.
- Metabolic and genetic changes in muscle suggest it is a viable therapeutic target.

## Abstract

In amyotrophic lateral sclerosis (ALS), a central event is the withdrawal of the motor nerve terminal from its target muscle. Whether this defect is driven by faults in the motor neuron or faults that originate within the muscle remains an area of investigation. In this review, we focus on the pathological abnormalities that are found in skeletal muscle, focusing, when possible, on human ALS, with support from ALS animal models. We begin with an overview of skeletal muscle, including a review of muscle fiber type, motor units and the neuromuscular synapse. Next, we provide a description of the clinical and biomarker changes that occur in the muscles of patients with ALS. We provide an extensive account of the histopathological changes that are evident in ALS muscle, such as fiber type grouping, muscle inflammation, protein misfolding, mitochondrial dysfunction, and alterations in neuromuscular junctions and muscle satellite cells. Our review then concludes with an update of metabolic and molecular–genetic changes that are found in ALS muscle. The evidence shows that muscle can be an additional target for therapy in ALS, in combination with therapies targeting neurons and glia within the central nervous system (CNS).